AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00715858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rifampin
Description: capsule, 300 mg, od, 12 months
Study NCT00715858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo matched to rifampin; placebo matched to doxycycline
Study NCT00715858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo matched to rifampin; placebo matched to doxycycline
Study NCT05233345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: online occupational therapy sessions are based on the activity training
Study NCT01065831 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Motivational interviewing (MINT-TLC)
Description: The MINT-TLC lifestyle intervention lead by lay health advisers will be compared to the health education attention control condition (CC). Twenty churches will participate in the study and each church will be randomly assigned to receive either MINT-TLC or CC. They will be compared on blood pressure reduction, physical activity levels, intake of fruits and vegetables, and weight reduction.
Study NCT01065831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MINT-TLC)
Description: The MINT-TLC lifestyle intervention lead by lay health advisers will be compared to the health education attention control condition (CC). Twenty churches will participate in the study and each church will be randomly assigned to receive either MINT-TLC or CC. They will be compared on blood pressure reduction, physical activity levels, intake of fruits and vegetables, and weight reduction.
Study NCT01353911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Orally once daily in AM. Blinded or open-label depending on treatment arm.
Study NCT01353911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Boceprevir
Description: Four 200 mg capsules orally three times daily.
Study NCT01353911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Grazoprevir
Description: Orally once daily in AM.
Study NCT01353911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Boceprevir
Description: Four capsules orally three times daily.
Study NCT02141997 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-122
Description: ABT-122 administered as subcutaneous injection every other week (EOW)
Study NCT02449174 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Frozen Microbiota
Description: Frozen Microbiota will be delivered via enema route.
Study NCT02449174 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lyophilized Microbiota
Description: Lyophilized Microbiota will be delivered orally.
Study NCT03685084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AAI101 i.v.
Description: 600 mg, 1 g, 2 g, 4 g, 1 g (every 6h), 2 g (every 6h)
Study NCT03685084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAI101 i.v.
Description: 600 mg, 1 g, 2 g, 4 g, 1 g (every 6h), 2 g (every 6h)
Study NCT03685084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9% infusion
Description: Vehicle infusion
Study NCT03685084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline 0.9% infusion
Description: Vehicle infusion
Study NCT03685084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin i.v.
Description: piperacillin 3 g i.v.
Study NCT03685084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime i.v.
Description: cefepime 1 g i.v.
Study NCT01184547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combex
Description: 12 weeks of exercise with a trainer post discharge.
Study NCT01184547 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: No exercise training received.
Study NCT01592344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StimRouter - active stimulation
Description: The stimulation program settings for this arm are as follows:~Stim Settings~* Waveform: Symmetric or Asymmetric~* Phase Duration: 100-250 µsec~* Pulse Rate: 50-100 Hz~* Intensity: 0-30mA Time Settings~* Constant Stim: On~* Total Time: 6 hour
Study NCT01592344 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: StimRouter - Control
Description: The stimulation program settings for this arm are as follows:~Stim Settings~* Waveform: Symmetric or Asymmetric~* Phase Duration: 200 µsec~* Pulse Rate: 1 Hz~* Intensity: 0 mA Time Settings~* Constant Stim: On~* Total Time: 6 hour
Study NCT03710655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apitox - pure honeybee toxin
Description: Intradermal injection of 0.01 microliters
Study NCT03710655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injection of 0.01 microliters
Study NCT02296385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Triple Strength Fish Oil
Description: Triple Strength Fish Oil
Study NCT02259361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sustained-release oral dalfampridine
Description: One Sustained-release oral dalfampridine; 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.
Study NCT02259361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.
Study NCT06093412 — intervention group
Intervention type: PROCEDURE
Intervention: unilateral epidural anesthesia
Description: The patients received unilateral epidural anesthesia
Study NCT06093412 — intervention group
Intervention type: PROCEDURE
Intervention: combined lumbar and epidural anesthesia
Description: The patients received combined lumbar and epidural anesthesia
Study NCT03031093 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: inhalation protocol
Description: technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution
Study NCT03031093 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: inhalation protocol
Description: technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution
Study NCT03031093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula
Description: aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula will deliver the aerosol at a 30L/min flow of oxigen.
Study NCT03536403 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: EOS X-rays
Description: EOS X-rays is done with et without a kyphosis induced corset
Study NCT03536403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8-meters walk test
Description: 8-meters walk test measured by optoelectronic Vicon system with et without a kyphosis induced corset
Study NCT00798109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational therapy
Description: One hour of motivational therapy each weak during 4 weeks
Study NCT00798109 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care
Description: Patients received at least six hour of usual therapy, as in the experimental group
Study NCT00387478 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tree MATA MPL or Tree MATA
Description: 4 injections of increasing dose strength for Tree MATA MPL or Tree MATA:~1. 600 SU/0.5 ml~2. 1600 SU/0.5 ml~3. 4000 SU/0.5 ml~4. 4000 SU/0.6 ml~4 injections of 0.5 mL of 2% w/v L-tyrosine for Placebo
Study NCT00387478 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Tree MATA MPL or Tree MATA
Description: 4 injections of increasing dose strength for Tree MATA MPL or Tree MATA:~1. 600 SU/0.5 ml~2. 1600 SU/0.5 ml~3. 4000 SU/0.5 ml~4. 4000 SU/0.6 ml~4 injections of 0.5 mL of 2% w/v L-tyrosine for Placebo
Study NCT04663581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Left Sided Colonoscopy
Description: Starting colonoscopy with the patient in left decubitus
Study NCT04663581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Right Sided Colonoscopy
Description: Starting colonoscopy with the patient in right decubitus
Study NCT02514837 — intervention group
Intervention type: DEVICE
Intervention: RTM
Description: Both the internal temperature and skin temperature will be measured non-invasively through the skin using the RTM device
Study NCT03759561 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intubation with videolaryngoscope vs fiberoptic bronchoscope
Description: Tracheal intubation was performed using either videolaryngoscope or fiberoptic bronchoscope under cervical collar application according to the group allocations
Study NCT02542332 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: With Data
Description: The participants received statistical data about lung cancer screening in order to help them answer the questionaire
Study NCT03302091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335
Description: 28 day treatment period
Study NCT01353911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-interferon alfa-2b
Description: 1.5 μg/kg/week subcutaneous injection.
Study NCT01277211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENG 120 µg + EE 15 µg intravaginal ring
Description: 13 cycles of ENG-EE (NuvaRing) vaginal ring use. Each cycle 28 days, with a 21-day active treatment period followed by 7-day ring-free period. One ring per cycle, each ring containing 11.7 mg ENG and 2.7 mg EE, and releasing on average 120 mcg/day of ENG and 15 mcg/day of EE.
Study NCT01277211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DRSP 3 mg + EE 30 µg
Description: 13 cycles of DRSP-EE tablet use. Each cycle 28 days, with a 21-day active treatment period followed by a 7-day tablet-free period. Participants received total of 21 tablets per cycle, each tablet contained 3 mg DRSP and 30 μg EE.
Study NCT04098510 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: Subjects ingest 8x20 mg MitoQ capsules
Study NCT00586534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I/GDC + VR/CER
Description: NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment plus virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions.
Study NCT00586534 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: I/GDC
Description: NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment
Study NCT00332852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg/day - oraly
Study NCT01819857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xomolix 0.625 mg intravenously
Description: intravenous administration of 0.625 mg droperidol
Study NCT01819857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xomolix 1.25 mg
Description: intravenous administration of 1.25 mg droperidol
Study NCT01819857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran 8 mg
Description: intravenous administration of 8 mg ondansetron
Study NCT03489811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Essential Oil Blend
Description: The test essential oil blend consists of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
Study NCT03514394 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The clinic's usual care includes counseling, substance use disorder treatment, peer support services, and some elements of traditional BA (not the modified BA).
Study NCT03514394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Behavioral Activation (Task Sharing)
Description: This intervention will include all core elements of Behavioral Activation (BA), which is a behavioral intervention that identifies work, social, health, or family activities that patients have stopped engaging in because of their mood. The intervention will also include a Task Sharing modification, which will allow clinicians and care managers to more efficiently share the tasks involved in BA.
Study NCT04307264 — intervention group
Intervention type: PROCEDURE
Intervention: Esophagogasrtoduodendoscopy, liver stiffness measurement
Description: Time frame between liver stiffness measurement and esophagogastroduodendoscopy is less than 2 weeks.
Study NCT01353911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-interferon alfa-2b
Description: 1.5 μg/kg/week subcutaneous injection.
Study NCT01353911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 300 mg to 700 mg orally twice daily.
Study NCT01353911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 300 mg to 700 mg orally twice daily.
Study NCT04348825 — intervention group
Intervention type: DEVICE
Intervention: Electroconvulsive therapy
Study NCT04052906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Planned Inhaler Medication Trainning
Study NCT03550508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-RANKL Monoclonal Antibody
Description: JMT103 is recombinant fully human anti-RANKL monoclonal antibody. JMT103 is provided as the injection,120 mg/vial. JMT103 was administered subcutaneously in the upper arm, upper thigh, or abdomen.
Study NCT01372020 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: neuromuscular electrical stimulation
Description: The application technique used will be bipolar, with electrodes of the type metal-tipped pen. The electrodes will be placed at the outer edges of the ulcer, on opposite sides of the same and the estimated time of 1 minute at each point. All the edge of the ulcer will be bypassed, thereby separating the injections every 1 cm, returning to the starting point at the end of the application. To ensure that the entire edge of the ulcer to receive the stimulation, the end points of the application, the application will be made for another minute sliding the pen around the whole edge. Thus the application time will be directly proportional to the ulcer area. The subjects will be received 10 applications, three times a week for a period of 4 weeks.
Study NCT01372020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuromuscular electrical stimulation
Description: The application technique used will be bipolar, with electrodes of the type metal-tipped pen. The electrodes will be placed at the outer edges of the ulcer, on opposite sides of the same and the estimated time of 1 minute at each point. All the edge of the ulcer will be bypassed, thereby separating the injections every 1 cm, returning to the starting point at the end of the application. To ensure that the entire edge of the ulcer to receive the stimulation, the end points of the application, the application will be made for another minute sliding the pen around the whole edge. Thus the application time will be directly proportional to the ulcer area. The subjects will be received 10 applications, three times a week for a period of 4 weeks.
Study NCT01619631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week Tai Chi intervention
Description: Tai Chi classes will be conducted weekly for one hour each for 12 weeks. Classes will begin with warm-up exercises designed to loosen the body, increase awareness of alignment and structural integration, improve efficiency of breathing, incorporate mindfulness and imagery into movement.
Study NCT01619631 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education control group
Description: The education control group will meet twice weekly for 12 weeks for one hour, and research staff will present didactic information modified from psychoeducation curriculums created by the Benson Henry Institute and a stress reduction study for depressed minority patients.
Study NCT01006798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: enteric coated capsule containing no vaccine virus
Study NCT04174287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18-AV45
Description: The study will enroll 200 patients with prodromal AD and mild AD dementia and 100 normal controls, men and women aged 55-80 years across core clinical criteria of prodromal AD and mild AD dementia based on IWG-2 criteria.
Study NCT02895945 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802)
Description: In case of major surgery, FVIII target level is ≥80% for major surgeries/ procedures and ≥50% for minor surgeries/ procedures.
Study NCT01006798 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-H5-Vtn
Description: a live, replication-competent, recombinant Ad4 virus expressing the HA of H5N1 influenza (A/Vietnam/1194/2004) in an enteric capsule for oral administration
Study NCT01006798 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sanofi Pasteur Influenza Virus Vaccine, H5N1
Description: Single administration of a heterologous boost given to volunteers 3 to 15 months following their last vaccination with Ad4-H5-Vtn or placebo.
Study NCT03849157 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor reconstructive surgery
Description: transvaginal mesh implantation for pelvic organ prolapse
Study NCT03632915 — intervention group
Intervention type: DRUG
Intervention: Levetiracetam
Description: Standard of care
Study NCT03632915 — intervention group
Intervention type: DRUG
Intervention: Lacosamide
Description: Standard of care
Study NCT03632915 — intervention group
Intervention type: DRUG
Intervention: Phenytoin
Description: Standard of care
Study NCT02706587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: NEMS is delivered bilaterally to the quadriceps femoris muscle using a portable battery-powered stimulator (Rehab 400, Cefar Compex, France). The electrodes are placed on the motor points of vastus medialis and vastus lateralis muscles. Electrical stimuli of 45Hz (pulse width: 380 µseconds; 6 seconds on with 1.5 second rise time; and 0.75 seconds fall time.; 5 seconds off). The current is adjusted to ensure maximum tolerable muscle contraction The protocol is applied twice daily for 25 minutes, five days a week.
Study NCT02706587 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: No electrostimulation
Study NCT00479479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)
Description: an intramuscular injection of 400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma, Norway)
Study NCT03481140 — intervention group
Intervention type: DEVICE
Intervention: TissuGlu Surgical Adhesive
Description: lysine-derived urethane adhesive
Study NCT03730415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Viscoelastic (VE) Guided Transfusion
Description: A viscoelastic analyzer (ROTEM) will be used to guide the transfusion algorithm during the burn wound excision of subjects enrolled into this arm
Study NCT03437824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyanocobalamin
Description: 1,000 mg, Once
Study NCT03437824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride, Once
Study NCT02219503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombitasvir/Paritaprevir/Ritonavir
Description: Tablet; paritaprevir co-formulated with ritonavir and ombitasvir
Study NCT02219503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasabuvir
Description: Tablet
Study NCT02580357 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: Low Level Laser Therapy on the palatal donor site of connective tissue graft.
Study NCT02580357 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Low Level Laser Therapy
Description: Low Level Laser Therapy on the palatal donor site of connective tissue graft.
Study NCT02580357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GaAlAs laser
Description: Utilization of GaAlAs laser to irradiation on the palatal donor site.
Study NCT02580357 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GaAlAs laser
Description: Utilization of GaAlAs laser to irradiation on the palatal donor site.
Study NCT04420156 — intervention group
Intervention type: OTHER
Intervention: No intervention administered.
Description: Eye exams are standard of care and would be performed regardless of participation in this study.
Study NCT04238351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transnasal humidified rapid insufflation ventilator exchange
Description: applying 40L of oxygen for 1min and afte that increase oxygen flow up to 70L for 1 min.
Study NCT04238351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional face mask
Description: applying oxygen using usual face mask
Study NCT01272830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules taken twice daily with meals